Welcome to The Multiple Sclerosis Journey. Join us for a multimedia exploration of where MS treatment and research stands, what the future of care may hold, and the experiences of clinicians and patients as they collaborate on the frontlines of MS care.
The Multiple Sclerosis Journey will examine new insights on the importance of early diagnosis as well as accurate identification of the four MS phenotypes and how their recognition impacts treatment selection. Join us as we examine the importance of maintaining brain health in sustaining wellness and ability among patients with MS. Experience discussions of the role of patient and physician collaboration in sustaining continuity of care and in tailoring therapy to individual patient needs and preferences.

And, importantly, view the impact of MS through the eyes of individual patients who generously tell their stories of how they build their lives around their abilities, not their disabilities.

The road to a cure for MS lies ahead. Along the way, clinicians, physicians, and patients are sharing their stories of working toward that goal at The Multiple Sclerosis Journey. We invite you to join them.

Walk with us.

Featured Articles

Ponesimod enters field of DMTs for relapsing forms of MS

The Food and Drug Administration has approved once-daily oral ponesimod (Ponvory, Janssen) for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Results from a pivotal phase 3 clinical trial show the drug was associated with nearly a third fewer annual relapses, compared with the MS drug teriflunomide.

Physical therapy interventions improve sexual health in MS

A range of physical therapy interventions – particularly pelvic floor muscle training and mindfulness training – can help alleviate sexual dysfunction in people with multiple sclerosis (MS), according to a new study.

Stem cell therapy for MS: Which patients is it right for?

Autologous hematopoietic stem cell transplant (AHSCT) shows promise for the treatment of relapsing multiple sclerosis (MS), but prospective clinical trials need to be done to confirm findings. The treatment could best be applied to patients aged under 50 years with disease duration less than 10 years, who are ineligible for disease-modifying therapies, or who have breakthrough symptoms with these treatments, such as clinical relapses or new inflammatory central nervous system lesions.

Gray-matter atrophy progresses swiftly in MS patients

Gray-matter atrophy was found in almost all the brain networks of patients with multiple sclerosis (MS), yet varies across phenotypes, a multicenter European study has confirmed, with atrophy in certain areas predicting disability and clinical worsening.

Different MS cognitive phenotypes could help guide care

Researchers have developed a new classification of cognitive function for patients with multiple sclerosis (MS) that is based on the identification of five cognitive phenotypes.